General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1 — At a Glance
Shilpa Medicare has spent most of a decade digging foundations. The company makes pharmaceutical ingredients and finished medicines, and runs research and manufacturing for other drug companies. India Ratings, a credit-rating agency, counts 11 facilities including research centres by March 2026. The comparable figure for the year to March 2020 was five. Capital spending between April 2020 and March 2026 came to roughly ₹1,700 crore. The year to March 2023 ended in a loss of ₹31 crore.
The three months to June 2026 read differently. Revenue was ₹466 crore, up 44.9% on a year earlier. Operating profit was ₹136 crore, against ₹91 crore. Profit after tax was ₹101 crore, against ₹47 crore. That is a rise of 115%. Management called it the highest-ever quarterly revenue and the fourth record quarter in a row.
The tax line does something unusual. The effective rate for the quarter was negative. The filing attributes that to a one-time reversal of deferred tax liability worth ₹26.84 crore. Deferred tax is tax carried in the accounts now for a bill settled later. The company is moving to the new regime under Section 200 of the Income-tax Act, 2025. Management expects the effective rate to settle at around 25%.
Elsewhere, India Ratings upgraded the bank facilities to IND AA- from IND A+ on 6 July 2026. A subsidiary bought 30% of a Spanish biotechnology company for 7 million euros. An antibody-drug conjugate plant was commissioned at Dharwad in June. Such drugs attach a toxin to an antibody that seeks out cancer cells. The chief executive of the subsidiary Shilpa Biologicals resigned on 15 July.
Sales growth measured over five years sits at 11.4% for the company.
2 — Introduction
Shilpa Medicare was incorporated in 1987 and came to the market in 1995. Vishnukant Bhutada is the promoter, and the head office sits in Raichur, Karnataka. The company makes niche active pharmaceutical ingredients, intermediates and finished formulations. An active pharmaceutical ingredient is the chemical that does the work inside a medicine. It also carries out contract research and manufacturing for other drug companies.
The structure has multiplied over the years. Consolidated results now take in fourteen subsidiaries and two joint ventures. Three associate companies sit alongside them. The named ones include Shilpa Pharma Lifesciences, Shilpa Biologicals, Shilpa Biocare and FTF Pharma. The group also holds Makindus Inc and an entity in Malaysia. Koanaa entities sit in the UK, Austria, Spain and Dubai, and the list runs longer. In February 2026 the National Company Law Tribunal sanctioned the absorption of Shilpa Therapeutics into the listed parent. The appointed date is 1 April 2025, accounted for under the pooling-of-interests method, which adds both sets of books together as though they had always been one.
Recent months have been busy on the disclosure front. In December 2025 the Delhi High Court issued an ex-parte ad-interim injunction affecting subsidiaries. It restrains the manufacture, stockpiling and sale of products containing Ruxolitinib and its salts. Ex-parte means the order was passed after hearing only one side. In February 2026 the company signed a development and commercial-supply agreement with NXI Therapeutics AG, covering a new chemical entity for autoimmune disease. Shilpa Biologicals licensed a biosimilar to SteinCares for Latin America in the same month. A biosimilar is a near-copy of a medicine grown in living cells rather than mixed chemically. In April, Dr Jayant Karajgi retired as chief operating officer for formulations, and Dr Vellaian Karuppiah was appointed. In June, Shilpa Biologicals signed a co-development and supply deal with Orion for a nivolumab biosimilar in Europe. In July, Dr Sridevi Khambhampaty resigned as chief executive of Shilpa Biologicals.
In October 2025 the company issued bonus shares, one for every share already held. Equity capital went from ₹9.78 crore to ₹19.56 crore. Earnings per share for earlier periods have been restated to match.
On 5 August 2026 the board approved results for the three months to June. It appointed Mr Sharath Reddy Kalakota as a whole-time director. The 39th annual general meeting is set for 11 September 2026.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3 — Business Model: WTF Do They Even Do?
There are three verticals, and the mix has moved.
Active pharmaceutical ingredients made up 50% of revenue in the year to March 2026. That share was 57% in the year to March 2025. The business runs through Shilpa Pharma Lifesciences. It covers cancer and non-cancer ingredients, intermediates, peptides and bio-polymers. Payloads and linkers for antibody drugs, and contract development work, sit here as well. Within the segment, cancer ingredients were 46% and non-cancer ingredients 40%. Specialty contract development accounted for 11% of the same segment.
Formulations, meaning finished medicines, were 40% of revenue against 37% the year before. They cover tablets, capsules, injectables and oral dissolving films, plus transdermal patches worn on the skin. Europe supplied 36% of formulation revenue, against 23% a year earlier. Licensing and services fell to 19% from 40%. The home market rose to 12% from 5%.
Biologics moved to 10% from 6%, and sits in Shilpa Biologicals
